Why choose the Oncomap ExTra test?
The Oncomap ExTra test combines the ultra-comprehensive genomic insights you expect from whole exome, whole transcriptome sequencing with the actionability and accessibility you and your patients need to inform crucial treatment decisions.
- Compare genes in both tumor (somatic) and normal (germline) DNA.
- Concomitant analysis of germline DNA allows for quick identification of true somatic alterations and maximizes the likelihood of identifying
tumor-specific variations with an accuracy of >99%.
Apply Deeper Genomic Insights
Whole Exome Sequencing
Identifies point mutations, amplifications and deletions, and translocations/structural variants in the full set of protein-coding genes and in therapeutically actionable non-coding regions (e.g., TERT promoter, common translocation junctions).
Whole Transcriptome Sequencing
Identifies the expression of RNA transcripts that may guide therapy (e.g., targetable gene fusions).
Tumor/normal exome subtraction—to help clearly distinguish somatic mutation from benign background variation
Results are presented in a single, integrated report with a cover page summarizing potentially clinically actionable findings, including:
Available therapeutic options
Clinical trial options
Markers to help guide checkpoint inhibitor therapy (MSI, TMB, and optional PD-L1 IHC)
Turnaround time is 14 days
Unstained slides: 10 from a single tumor, ≥ 50 microns total + H&E slide